Updated pediatric guideline on antibacterial and antifungal prophylaxis in cancer

The Pediatric Oncology Group of Ontario updated and harmonized its clinical practice guidelines for systemic antibacterial and antifungal prophylaxis, incorporating 13 new randomized trials for a total of 195. The panel maintained conditional recommendations to consider antibacterial prophylaxis in AML and relapsed ALL, strong recommendations for levofloxacin when antibacterial prophylaxis is used, and strong recommendations for antifungal prophylaxis with an echinocandin or mold-active azole in AML and allogeneic HCT recipients, while adding a new conditional recommendation for patients unable to receive levofloxacin and three new good practice statements.

Most relevant for: Pediatric patients with cancer, including those with AML or relapsed ALL, and pediatric allogeneic hematopoietic cell transplant recipients.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.